Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Cunningham D, et al. Among authors: qian w. Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22. Lancet. 2013. PMID: 23615461 Free article. Clinical Trial.
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Ardeshna KM, et al. Among authors: qian w. Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4. Lancet Oncol. 2014. PMID: 24602760 Clinical Trial.
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW. Hoskin PJ, et al. Among authors: qian w. J Clin Oncol. 2009 Nov 10;27(32):5390-6. doi: 10.1200/JCO.2009.23.3239. Epub 2009 Sep 8. J Clin Oncol. 2009. PMID: 19738111 Clinical Trial.
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M. Linch DC, et al. Among authors: qian w. Br J Haematol. 2010 Apr;149(2):237-43. doi: 10.1111/j.1365-2141.2010.08081.x. Epub 2010 Mar 1. Br J Haematol. 2010. PMID: 20201949 Free article. Clinical Trial.
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Moore S, Kayani I, Peggs K, Qian W, Lowry L, Thomson K, Linch DC, Ardeshna K. Moore S, et al. Among authors: qian w. Br J Haematol. 2012 Jun;157(5):543-52. doi: 10.1111/j.1365-2141.2012.09096.x. Epub 2012 Mar 20. Br J Haematol. 2012. PMID: 22429186 Free article.
Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy.
El-Sharkawi D, Basu S, Ocampo C, Qian W, D'Sa S, Hoskin PJ, Ardeshna KM. El-Sharkawi D, et al. Among authors: qian w. Leuk Lymphoma. 2012 Oct;53(10):1949-52. doi: 10.3109/10428194.2012.679360. Epub 2012 May 22. Leuk Lymphoma. 2012. PMID: 22462615
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S, Mackinnon S, Hoskin PJ, Goldstone AH, Linch DC. Ardeshna KM, et al. Among authors: qian w. Br J Haematol. 2005 Aug;130(3):363-72. doi: 10.1111/j.1365-2141.2005.05603.x. Br J Haematol. 2005. PMID: 16042685 Free article.
3,960 results